Related Experiment Video
Updated: Feb 15, 2026

Quantification of Immunostained Caspase-9 in Retinal Tissue
Published on: July 25, 2022
Proprotein Convertase Subtilisin/kexin type 9 Inhibition in Cardiovascular Prevention
Ali Ali1, Pierluigi Costanzo1, Angela Hoye1
1Department of Academic Cardiology, University of Hull, Kingston upon Hull, United Kingdom.
Insights
High LDL-C increases cardiovascular risk. While statins help, some patients need more. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors offer a new therapeutic option for managing cholesterol effectively.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Biochemistry
Background:
- Elevated Low Density Lipoprotein cholesterol (LDL-C) is a primary risk factor for atherosclerotic cardiovascular and cerebrovascular diseases.
- Statins effectively reduce cardiovascular events but may not achieve adequate LDL-C control in all patients, especially those with familial hypercholesterolemia.
Purpose of the Study:
- To review the development and application of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
- To highlight PCSK9 inhibitors as a novel therapeutic strategy for managing hypercholesterolemia.
Main Methods:
- Literature review of studies on PCSK9 inhibitor development.
- Analysis of clinical data regarding the efficacy and use of PCSK9 inhibitors.
Main Results:
- PCSK9 inhibitors represent a significant advancement in lipid-lowering therapy.
- This class of drugs offers an effective alternative for patients with statin-intolerant or statin-resistant hypercholesterolemia.
Conclusions:
- PCSK9 inhibitors provide a new and effective therapeutic avenue for managing elevated LDL-C.
- Their development addresses the unmet need for improved cholesterol control in specific patient populations, reducing cardiovascular risk.
Abstract:
Elevated levels of Low Density Lipoprotein cholesterol (LDL-C) are directly associated with increased risk for atherosclerotic cardiovascular and cerebrovascular events. Statins have been used to control serum LDLC and this has translated into reduction in cardiovascular and cerebrovascular events. However, despite high dose statin therapy, LDL-C control may remain inadequate in some patients, particularly those with familial hypercholesterolemia. A new therapeutic approach has emerged in recent years with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. In this review, we describe the development and the use of this new class of drugs.
Related Concept Videos
Feedback Inhibition
Overview of the Cardiovascular System
Heart
The heart is the central pump of the cardiovascular system that circulates blood throughout the body. It comprises two atria receiving the blood and two ventricles pumping blood out of the heart. Their rhythmic contractions, called heartbeats, ensure that blood flow remains continuous.
Blood Vessels
Blood...
Cancer Prevention
Some...
Regulation of the Cardiovascular System
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
Enzyme Inhibition
Prevention of Further Absorption of Poison

